caa a22 4500 477054617 CHVBK 20180405111344.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/BF02602954 doi (NATIONALLICENCE)springer-10.1007/BF02602954 The effect of cefodizime on phagocyte function in non-patient volunteers and patients with chronic renal failure [Elektronische Daten] In vitro and ex vivo studies [A. McCafferty, E. McGregor, M. Jones, I. Henderson, I. Cree] Cefodizime has previously been shown to possess a number of immunomodulating properties in vivo and in vitro using several different test systems. Since most in vitro studies have been performed with cells from normal individuals, we first investigated whether cells from chronic renal failure patients would respond in vitro to cefodizime in the same way as healthy subjects. Subsequently, we investigated the effect of cefodizime (10 gover 10 days in 2-g doses) on phagocyte function ex vivo in an open study of 26 chronic renal failure patients and 16 healthy subjects. Polymorphonuclear leukocytes were tested for their ability to polarize in response to cefodizime and/or f-met-leu-phe peptide. Polymorphonuclear leukocytes and monocytes were tested for their ability to produce chemiluminescence on stimulation with either phagocytic (zymosan) or soluble phorbol myristate acetate stimuli. Phagocyte and lymphocyte membrane receptor expression was compared after exposure to cefodizime. Exposure to cefodizime in vitro causes a significant increase in polarization of polymorphonuclear leukocytes from both normal individuals and renal failure patients (bothP<0.001). It also caused increased chemotaxis and chemokinesis in a modified Boyden chamber assay. Cefodizime did not affect lucigenin-enhanced chemiluminescence and there were only minor effects on cell membrane antigen levels. In the ex vivo study there was a significant increase in polymorphonuclear leukocyte polarization (P<0.001) attributable to cefodizime, but other investigations showed no significant differences. The results suggest that cefodizime may act as a mild priming agent for some functions, particularly chemotaxis. Springer-Verlag, 1996 Chronic renal failure nationallicence Chemiluminescence nationallicence Phagocytes nationallicence Cefodizime nationallicence Polarization nationallicence McCafferty A. Knight Scientific Ltd., The Laboratory, 18 Western College Road, PL4 7AG, Plymouth, UK aut McGregor E. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut Jones M. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut Henderson I. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut Cree I. Department of Pathology, Institute of Ophthalmology, University College London, Bath Street, EC1V 9EL, London, UK aut International Journal of Clinical and Laboratory Research Springer-Verlag 26/4(1996-12-01), 229-235 0940-5437 26:4<229 1996 26 599 https://doi.org/10.1007/BF02602954 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02602954 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McCafferty A. Knight Scientific Ltd., The Laboratory, 18 Western College Road, PL4 7AG, Plymouth, UK aut NATIONALLICENCE 700 1- McGregor E. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut NATIONALLICENCE 700 1- Jones M. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut NATIONALLICENCE 700 1- Henderson I. Department of Renal Medicine, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK aut NATIONALLICENCE 700 1- Cree I. Department of Pathology, Institute of Ophthalmology, University College London, Bath Street, EC1V 9EL, London, UK aut NATIONALLICENCE 773 0- International Journal of Clinical and Laboratory Research Springer-Verlag 26/4(1996-12-01), 229-235 0940-5437 26:4<229 1996 26 599 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer